Navigation Links
Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
Date:7/2/2012

ANAHEIM, Calif., July 2, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:  QCOR) announced today that executive management will present at the JMP Securities Healthcare Conference in New York on July 13, 2012 at 8:00 a.m. PT / 11:00 a.m. ET.

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently preparing to launch a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
2. Pharmaceuticals: Global Industry Almanac, MarketLine
3. Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
4. Nouveau Life Pharmaceuticals (NOUV) to Launch Affiliate Sales Program
5. Trading Of Onyx Pharmaceuticals Common Stock Halted
6. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
7. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
8. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
9. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
10. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
11. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2019)... CHATTANOOGA, Tenn. (PRWEB) , ... December 13, 2019 ... ... Randall help patients suffering from gum disease in Chattanooga, TN receive ... disease treatment into their practice, Drs. Felts and Randall provide effective gum disease ...
(Date:12/9/2019)... ... December 09, 2019 , ... Medpricer™, which ... across purchased services contracts, today announced its latest partnership with San Diego-based Sharp ... with four acute care hospitals, three specialty hospitals, three affiliated medical groups, 22 ...
(Date:12/8/2019)... ... December 07, 2019 , ... ... medical affairs, regulatory, and technology-enabled solutions, announced that MAIA Pharmaceuticals, Inc. (MAIA), a ... products has chosen Soterius and its partners in Europe, to support their regulatory ...
Breaking Medicine Technology:
(Date:12/9/2019)... ... 2019 , ... John V. Prunskis, MD., co-founder and co-Medical ... Human Services' (HHS) Pain Management Best Practices Inter-Agency Task Force (Pain Task Force) ... in Washington DC. , Hosted by the Alliance for Balanced Pain Management, the ...
(Date:12/9/2019)... ... 09, 2019 , ... Cocoa Beach is preparing to host its 10th annual ... Santa-themed gatherings. , What began as a simple family beach day a decade ago ... Now, ten years in, there’s no better place for Santa to loosen up as ...
(Date:12/6/2019)... ... December 06, 2019 , ... C&A Industries ... in employee learning. The Omaha-based company has been named by Training magazine to ... employer-sponsored training and development programs worldwide. Rankings of the 125 leading companies will ...
(Date:12/6/2019)... DENVER (PRWEB) , ... December 06, 2019 , ... Lasair Aesthetic Health Sponsors Toys for ... Five Units of Botox to Patients Who Bring in Toys During the Holidays , Lasair ... program. From now until Christmas, patients who bring in a toy or toys worth more ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... high resolution ultrasound (HRUS) technology to help their patients more easily detect ruptured ... is participating in this study and reporting on his experience. While the FDA ...
Breaking Medicine News(10 mins):